bioAffinity Technologies announced a new pilot study with the U.S. Army’s Brooke Army Medical Center (BAMC) to evaluate its proprietary flow‑cytometry and artificial‑intelligence platform on sputum samples from patients with asthma, chronic obstructive pulmonary disease (COPD), and healthy controls. The study will enroll roughly 40 participants across three cohorts and will assess the platform’s ability to identify and quantify immune cell populations and cytokines that could guide precision treatment decisions.
The collaboration marks a strategic expansion of bioAffinity’s CyPath Lung technology beyond early‑stage lung cancer detection. By applying the same platform to asthma and COPD, the company targets a $92 billion market and aims to broaden its portfolio of non‑invasive respiratory diagnostics for both military and civilian healthcare systems. The use of sputum, a non‑invasive sample, aligns with the company’s goal of reducing costs and turnaround times through automated analysis.
Financially, bioAffinity remains unprofitable. For the year ended December 31, 2025, the company reported a net loss of $14.9 million, up from $9.0 million in 2024, and revenue of $6.2 million, down 34% from $9.4 million in 2024. The decline reflects a strategic decision to discontinue unprofitable pathology services and reallocate resources to CyPath Lung. In contrast, revenue from CyPath Lung grew 87% year‑over‑year in 2025, with unit sales increasing 99%, and the company raised $16.9 million in equity during the year.
Management has forecast that CyPath Lung unit sales will more than double in 2026 compared with 2025, signaling confidence in continued demand for the platform. The company’s focus on high‑growth diagnostics and the discontinuation of legacy services underscore a shift toward a more scalable, technology‑driven business model.
BAMC, the largest U.S. Army medical center, provides a credible and sizable patient population for the study. The partnership enhances bioAffinity’s credibility and could facilitate future regulatory approvals and commercial deployments in both military and civilian settings.
The announcement is a material event for investors, as it represents a potential new revenue stream and a significant shift in the company’s product strategy. The pilot study’s outcomes could influence the company’s future growth trajectory and market positioning.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.